Vitamin D receptor activation with calcitriol for reducing urinary angiotensinogen in patients with type 2 diabetic chronic kidney disease

• DOI: 10.3109/0886022x.2015.1128250
• Publication Date: 2015-12-27T21:44:41Z
• Authors: Özlem Tiryaki; Celalettin Usalan; Zeynel Abidin Say...
• Keywords: Albuminuria

Background Recently, it has been reported that urinary angiotensinogen levels is a specific index of the intrarenal renin-angiotensin-aldosterone system (RAAS) status and significantly correlated with albumin:creatinine (Cr) ratio in hypertensive patients. The aim present study was to assess effect activation Vitamin D receptor calcitriol on albuminuria as novel biomarker intra-renal RAAS patients diabetic nephropathy (DN). Methods Ninety-eight type 2 diabetes who were treated inhibitors (angiotensin-converting enzyme inhibitor (ACE-i) or angiotensin blocker (ARB)) have participated this study. Patients randomized receive either placebo (n = 50) 0.25 μg/day 48). We examined albumin:Cr angiotensinogen:Cr before 24 weeks later after treatment both group. Results mean higher DN than normal controls (p < 0.001). Urinary significantly, positively groups (in group; p 0.01, r 0.4236, 0.4564). Conclusion These data indicated administration activator combination had an additional benefit lowering DN. More pronounced reduction group suggested might blunt by reducing reflecting status.